Compare GPOR & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPOR | KTTA |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 18.1M |
| IPO Year | 1998 | 2021 |
| Metric | GPOR | KTTA |
|---|---|---|
| Price | $155.91 | $0.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $233.33 | $3.00 |
| AVG Volume (30 Days) | ★ 223.9K | 205.8K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 245.92 | 77.07 |
| EPS | ★ 13.82 | N/A |
| Revenue | ★ $1,422,583,000.00 | $486,559.00 |
| Revenue This Year | $18.35 | N/A |
| Revenue Next Year | $6.04 | N/A |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | 48.47 | ★ 3130.37 |
| 52 Week Low | $149.18 | $0.28 |
| 52 Week High | $225.78 | $2.06 |
| Indicator | GPOR | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 34.48 | 42.86 |
| Support Level | $149.18 | $0.48 |
| Resistance Level | $173.70 | $0.52 |
| Average True Range (ATR) | 5.19 | 0.03 |
| MACD | -2.09 | -0.01 |
| Stochastic Oscillator | 4.02 | 17.06 |
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets located in the Appalachia and Anadarko basins in the United States. The principal properties of the company are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.